Scientists from Trinity College Dublin, Dublin City University, and University College Dublin have embarked on a transformative project centered on the early detection of colorectal cancer (CRC), harnessing recent funding of €670,000 from Enterprise Ireland’s Commercialisation Fund. This initiative aims to develop a pioneering blood-based screening test—CASPDx CRC—that promises to revolutionize the current landscape of bowel cancer diagnostics by offering a simpler, less invasive, and more accurate alternative to traditional methods.
Colorectal cancer remains a formidable global health challenge, ranking as the second leading cause of cancer-related deaths according to the World Health Organization. Despite advancements in treatment, a significant hurdle remains: the majority of CRC cases are detected at late stages, severely limiting therapeutic options. Contributing to this problem is the reliance on existing screening modalities such as colonoscopies and stool-based kits, which suffer from low patient compliance due to their invasive or unpleasant nature, as well as suboptimal accuracy in identifying early-stage cancers.
The CASPDx CRC test seeks to circumvent these issues by detecting specific inflammatory biomarkers in the bloodstream—molecular signals intricately linked to the tumor microenvironment and the progression of colorectal malignancies. Dr. Emma Creagh, the scientific lead and Associate Professor of Biochemistry at Trinity College Dublin, explains that inflammation plays a dual role, essential for immune surveillance and tissue repair yet paradoxically facilitating cancer development and spread when dysregulated. Their research identifies precise inflammatory markers whose elevated presence in the blood correlates with CRC onset and advancement, enabling this blood test to serve as an early warning system for patients at risk.
This cutting-edge diagnostic approach is currently undergoing formal validation across multiple Bowel Screen Centres in the Health Service Executive’s Dublin and South East region, supported by collaboration with the UCD Clinical Research Centre. These multicentric clinical studies are critical to establishing the test’s sensitivity, specificity, and reproducibility before its anticipated market introduction, aimed for late 2027. Successful commercialization will facilitate widespread access, bridging the gap between scientific innovation and clinical application.
CRC presents a particular concern in younger populations, evidenced by a near doubling in incidence rates among individuals under 50 over the past three decades. Alarmingly, early-onset colorectal cancer often manifests more aggressively and is diagnosed at more advanced stages, partly due to screening protocols that typically commence at or after the age of 50. Consequently, the CASPDx CRC test could also redefine screening paradigms by facilitating earlier detection in younger, otherwise undiagnosed demographics.
Dr. Kieran Clarke, Commercial Lead for CASPDx, underscores the urgent need for better diagnostics by highlighting the vast numbers of unscreened individuals—estimated at nearly 120 million across the US and EU. The envisioned test combines affordability and scalability with high diagnostic accuracy, attributes that are essential for integration into existing healthcare systems and national screening programs. Clarke emphasizes that the support from Enterprise Ireland’s fund enables the recruitment of specialized teams needed to accelerate development, validate the assay clinically, and ultimately transfer the technology from laboratory to patient care.
A pressing challenge in CRC management is the burden placed on healthcare infrastructures by invasive diagnostics such as colonoscopy, which not only cause discomfort to patients but also face long waiting lists. Prof. Glen Doherty, Consultant Gastroenterologist at St Vincent’s University Hospital, stresses that a reliable blood-based screening tool could significantly refine patient triage pathways. By accurately distinguishing true positives following initial stool test screening, the CASPDx CRC test promises to optimize colonoscopy utilization, reduce unnecessary procedures, and allow resources to focus on patients with confirmed malignancies.
The socio-economic impact of colorectal cancer is profound. The disease was estimated to cost the European Union approximately €19 billion in 2020 alone, a figure reflecting direct healthcare expenses, lost productivity, and broader societal impacts. Current diagnostics, particularly novel technologies offering enhanced accuracy, often remain prohibitively expensive and geographically limited, underscoring the value of CASPDx’s approach in democratizing access to quality screening.
Enterprise Ireland’s Research Commercialisation Unit has recognized the potential of CASPDx, endorsing it as a paradigm-shifting technology in the colorectal cancer screening arena. Their funding is instrumental in supporting an interdisciplinary team from academia and clinical practice, fostering innovation that merges cutting-edge biochemistry, immunoassay development, and clinical expertise.
At the heart of this initiative is a multidisciplinary leadership ensemble combining scientific acumen, clinical insight, and commercial expertise. Alongside Dr. Emma Creagh, the team includes Dr. Paul Leonard, Development Lead at Dublin City University, who brings extensive experience in molecular biology and recombinant antibody technology—key to the development of sensitive immunoassays tailored to inflammatory markers. Dr. Kieran Clarke’s background in launching diagnostic products internationally complements this expertise, and Prof. Glen Doherty provides essential clinical guidance rooted in his frontline gastroenterological experience.
This collaboration exemplifies the model of translational research where fundamental biochemical discoveries about inflammation and its connection to cancer are harnessed to create tools with the potential to save lives. The CASPDx CRC test is emblematic of precision diagnostics that move beyond symptom-based detection to molecularly informed screening, enhancing early intervention opportunities.
In summary, the CASPDx CRC test represents a beacon of hope in colorectal cancer diagnostics, promising a more patient-friendly, cost-effective, and accurate screening alternative. By intercepting cancer development through the detection of blood-based inflammatory biomarkers, it aims not only to improve survival rates but also to alleviate healthcare burdens. As clinical trials and validation efforts progress, the global healthcare community watches with anticipation for this transformative innovation poised to reshape the future of bowel cancer screening.
Subject of Research: Development of a blood-based screening test for colorectal cancer using inflammatory biomarkers
Article Title: Breakthrough Blood Test Promises Early Detection of Colorectal Cancer through Inflammatory Biomarkers
News Publication Date: Information not provided
Web References: Information not provided
References: Information not provided
Image Credits: Thomas Deane, Trinity College Dublin
Keywords: colorectal cancer, blood-based screening, inflammatory biomarkers, cancer diagnostics, CASPDx, early detection, colorectal cancer screening, immunoassay development, cancer inflammation, non-invasive diagnostics, cancer biomarker test, clinical validation
